Erasca, Inc.
NASDAQ:ERASBiotechnology
-$0.02 today
- Market cap
- $4.83B
- Beta
- 0.73
- P/E (TTM)
- -15.3
- EPS (TTM)
- -$0.91
Volume 8.94M
Average 6.79M
ERAS Common Stock Issued
Cash raised by issuing new shares.
Erasca, Inc.NASDAQ: ERAS
Common Stock Issued · Q3 FY2026 · quarter ended Sep 2026
Common stock issued growth accelerates
Q3 FY2026 common stock issued of $597.5M rose 1457224.4% year over year, ahead of the +63902.0% change in trailing-twelve-month common stock issued. Sequentially, it rose 17661.7% from the prior quarter. Over 3 fiscal years it compounded at -77.4% a year.
Context
- Common stock issued increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +1457224.4% holds above the trailing-twelve-month pace of +63902.0%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Common Stock Issued history
USD · from the cash flow
- Latest · FY2025
- 1.1M USD
- Year-over-year change
- -99.5%
- 4-year CAGR
- -75.8%
| Period | Period end | Common Stock Issued | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.1M | -99.5% |
| FY2024 | 2024-12-31 | 239.06M | +18360.3% |
| FY2023 | 2023-12-31 | 1.3M | -98.6% |
| FY2022 | 2022-12-31 | 95.25M | -70.0% |
| FY2021 | 2021-12-31 | 317M | — |
Common Stock Issued vs competitors
How ERAS compares with its peers on the latest reported figures
- ERAS's LTM Sep 2026 common stock issued of $846.11M is the 3rd largest of the 9 companies compared; the peer median is $233.93M.
- Its year-over-year change of +63902.0% is the highest of 9, against a peer median of +306.6%.
- Over three fiscal years its annual growth of -77.4% compares with a peer median of +55.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $2.3B | +140.5% | +8.2% | — | |
| LTM Sep 2026 | $975.5M | +31146.1% | — | — | |
| LTM Sep 2026 | $846.11M | +63902.0% | -77.4% | — | |
| LTM Mar 2026 | $308M | +17301.2% | +114.8% | — | |
| LTM Mar 2026 | $251.58M | +3182.6% | +4561.9% | — | |
| LTM Mar 2026 | $216.27M | +376.4% | +103.6% | 436.2% | |
| LTM Mar 2026 | $4.82M | -98.6% | -32.1% | 2.1% | |
| LTM Jun 2026 | $4.36M | +236.8% | — | 2.6% | |
| LTM Mar 2026 | $1.2M | -62.2% | -58.3% | 1.7% | |
| Peer median (excluding ERAS) | $233.93M | +306.6% | +55.9% | 2.4% | |
Competitors are the stored peer set for ERAS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (122.76M) | (242.81M) | (125.04M) | (161.65M) | (124.55M) |
| Depreciation & Amortization | 829K | 2.64M | 3.73M | 3.81M | 3.11M |
| Deferred Income Tax | (1.51M) | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 8.33M | 20.11M | 26.23M | 26.97M | 24.9M |
| Change in Working Capital | 7.71M | 15.79M | 813K | 1.74M | (3.33M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 1.34M | 676K | (886K) | (1.53M) | 513K |
| Other Working Capital | 6.36M | 15.11M | 1.7M | 3.27M | (3.84M) |
| Other Non-Cash Items | 27.81M | 101.01M | (6.95M) | 19.72M | 4.41M |
| Operating Cash Flow | (79.6M) | (103.26M) | (101.22M) | (109.42M) | (95.46M) |
| Capital Expenditures | (18.89M) | (16.55M) | (1.78M) | (22.56M) | (128K) |
| Acquisitions (Net) | 7.68M | 4M | 0 | 0 | 0 |
| Purchases of Investments | (105.82M) | (134.33M) | (314.39M) | (403.38M) | (150.97M) |
| Sales of Investments | 60.11M | 79.8M | 244.95M | 269.33M | 261.03M |
| Other Investing Activities | (7.68M) | (4M) | (20M) | (22.5M) | (9.5M) |
| Investing Cash Flow | (64.59M) | (71.08M) | (91.22M) | (156.62M) | 100.43M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 317M | 95.25M | 1.3M | 239.06M | 1.1M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 3.01M | 2.82M | 0 | 1.64M | 0 |
| Financing Cash Flow | 439.4M | 98.08M | 1.3M | 240.7M | 1.1M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 295.21M | (76.27M) | (191.14M) | (25.34M) | 6.07M |
| Free Cash Flow | (98.49M) | (119.82M) | (102.99M) | (131.98M) | (95.58M) |
Erasca, Inc.
NASDAQ:ERAS
Intrinsic Alpha fair value
Locked
Current Price
$13.76
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.